Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03987074 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT03987074 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 109 participants.
The verdict
NCT03987074, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of study drug(s) in participants with nonalcoholic steatohepatitis (NASH).
Interventions
- DRUG Semaglutide
- DRUG Cilofexor
- DRUG Firsocostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2019-07-29 |
| Est. Completion | 2020-07-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03987074
The ClinicalTrials.gov registry entry for NCT03987074 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Semaglutide is the first listed.
NCT03987074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03987074 about?
NCT03987074 is a clinical study titled "Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)". The primary objective of this study is to evaluate the safety and tolerability of study drug(s) in participants with nonalcoholic steatohepatitis (NASH).
What is the current status of trial NCT03987074?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2019-07-29. Estimated completion is 2020-07-13.
What interventions are being tested in trial NCT03987074?
The interventions under investigation include: Semaglutide (DRUG), Cilofexor (DRUG), Firsocostat (DRUG).
Who is sponsoring clinical trial NCT03987074?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.